Idasanutlin (Roche) is an oral inhibitor of the murine double minute 2 (MDM2) protein, which blocks the interaction of MDM2 with the p53 tumor suppressor. Inhibition of MDM2/p53 interaction by idasanutlin restores the tumor-suppressing function of the p53 protein and has been shown to induce apoptosis of cancer cells in preclinical models.
LIST OF FIGURES
8 Figure 1: Idasanutlin for acute myeloid leukemia – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of idasanutlin for acute myeloid leukemia
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of idasanutlin for acute myeloid leukemia
LIST OF TABLES
5 Table 1: Idasanutlin drug profile
6 Table 2: Idasanutlin Phase III trial in acute myeloid leukemia
7 Table 3: Idasanutlin Phase I/Ib data in acute myeloid leukemia
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.